Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$0.178
HK$0.00 · 0.00%
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
Latest quote
HK$0.178
HK$0.00 · 0.00%
Regular session · HKT · Market data may be delayed.
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
52-week range
Current HK$0.178
Regular session · HKT · Market data may be delayed.
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
52-week range
Current HK$0.178
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 28.28M CNY | 25.36M CNY | 24.63M CNY | 25.33M CNY | 26.13M CNY |
| Cost of goods sold | 10.51M CNY | 8.29M CNY | 8.54M CNY | 8.42M CNY | 9.67M CNY |
| Gross profit | 17.77M CNY | 17.07M CNY | 16.09M CNY | 16.91M CNY | 16.46M CNY |
| Research and development | 3.93M CNY | 2.83M CNY | 2.55M CNY | 2.48M CNY | 2.44M CNY |
| Selling, general, and administrative | 22.41M CNY | 19.26M CNY | 18.49M CNY | 18.75M CNY | 17.7M CNY |
| Operating expenses | 26.34M CNY | 22.08M CNY | 23.48M CNY | 22M CNY | 20.24M CNY |
| Interest income | 315.61K CNY | 512K CNY | 404K CNY | 409K CNY | 179K CNY |
| Interest expense | 239.63K CNY | 86K CNY | 53K CNY | 55K CNY | 102K CNY |
| Depreciation and amortization | 1.72M CNY | 1.6M CNY | 3.18M CNY | 3.14M CNY | 2.95M CNY |
| Operating income | −7.81M CNY | −5.01M CNY | −7.39M CNY | −5.09M CNY | −4.58M CNY |
| Net income | −5.01M CNY | −4.16M CNY | −5.78M CNY | −3.08M CNY | −4.22M CNY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
